Name in SEC filings: Xenon Pharmaceuticals Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| NBI-921355 | /data readout | Phase 1 | 2027 | 10-Q · |
Source: ORION, orionbiotechai.com/company/XENE, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/XENE
NBI-921355 · Topline/data readout · 2027
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout2027
Stage: Phase 1SEC filing · “Phase 1b; Phase 1b”
Public float: $2,404,900,000 · as of · SEC filing
a Phase 1b study is ongoing for NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6 in development for the potential treatment of certain types of epilepsy. Data from the Phase 1b study are expected in 2027.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| NBI-921355Clinical results | 2027“a Phase 1b study is ongoing for NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6 in development for the potential treatment of certain types of epilepsy. Data from the Phase 1b study are expected in 2027.” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| NBI-921355Clinical results | 2027“Data from the Phase 1b study are expected in 2027.” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| NBI-921355Clinical results | 2027“Data from the Phase 1b study are expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for XENE. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See XENE in the calendar · Review labels and methodology